GLAXOSMITHKLINE has confirmed the closure of its manufacturing site in the Sydney suburb of Ermington, with the facility to cease operation in 2020.
GSK Consumer Healthcare said the decision was made after a thorough evaluation of the site which found it would not be able to remain competitive long term.
Michael Tyler, GSK VP Asia Middle East & Africa Supply Chain said "unfortunately significant ongoing investment would be needed to maintain our Ermington manufacturing facility, making it uncompetitive".
The operation will be phased out over the next four years, with production to be gradually transferred to other manufacturing sites in the GSK network as well as third party contract manufacturers.
About 223 jobs will become redundant with the closure, with GSK saying all entitlements for the affected staff are protected.
GSK said it doesn't anticipate any impact on the availability of products currently made at Ermington, with the company working hard to ensure continuity of supply for consumers.
The move may also result in the relocation of the existing GSK Consumer Healthcare commercial offices based in Ermington.
The above article was sent to subscribers in Pharmacy Daily's issue from 04 Nov 16
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 04 Nov 16
